Changes of central macular thickness post intravitreal ranibizumab and its associated factors among diabetic macular oedema patients
Background: Intravitreal Ranibizumab (IVR) which is an anti-vascular endothelial growth factor (anti-VEGF) has become the preferred treatment option to improve the vision of diabetic macular oedema (DMO) patients. IVR acts by inhibits VEGF-A from binding to its receptors, leading to decreased in vas...
| Auteur principal: | |
|---|---|
| Format: | Thèse |
| Langue: | anglais |
| Publié: |
2020
|
| Sujets: | |
| Accès en ligne: | http://eprints.usm.my/51000/ |